Biognosys is the world leader in the application of next-generation proteomics solutions to accelerate your research and drug development timelines.
The limited success of disease-modifying drugs for neurological disorders highlights the urgent need for better biomarkers and a deeper understanding of the underlying biology.
Proteomics can provide unprecedented functional insights into the molecular basis of complex neurological disorders, bringing hidden pathways and new therapeutic targets to light.
Here are some examples of how we have applied proteomics to address key questions in neuroscience drug discovery and development.
Global proteomic profiling of CSF to identify novel disease biomarkers
Progress in neurodegenerative conditions such as Alzheimer’s disease has been hindered by a lack of knowledge about the underlying biological processes and relevant biomarkers. By applying Biognosys’ Discovery Proteomics workflow, we deeply characterized the proteome of cerebral spinal fluid samples (CSF) of Alzheimer’s patients to identify proteins and pathways implicated in the progression of the disease.
Case study: Global Proteomic Profiling of CSF to Identify Disease Biomarkers of Neurodegeneration
Application: Biomarker Discovery
Proteome-wide characterization of the binding specificity and selectivity of small molecules
Biognosys’ drug Target Deconvolution approach Limited Proteomics Mass Spectrometry (LiP-MS) can effectively identify protein drug targets and characterize their binding properties in complex proteomes without the need for compound modification or labeling.
In this specific example, LiP-MS was used to distinguish the specificity and selectivity of different kinase and phosphatase inhibitors.
Case Study: Target Deconvolution of Drug Specificity and Selectivity
Technology Video: LiP-MS: A Novel Target Deconvolution Approach
Application: Target Deconvolution
Let us help you do great proteomics!
Please click here to contact us.
